EUVIMEDEUVIMED entdecken
Klinische Studie

Efficacy and Safety of Vonoprazan-Amoxicillin Dual Therapy for Helicobacter pylori Infection Among People Living With HIV

Jinzhi Zhang, Ying Wang, Liyu Chen, Ping Feng, Xiaona Song, Yalin Shen, Fanghua Ma, Alfred C Y Tay, Barry J Marshall, Hong Tang, Hong Li iD

The Journal of Infectious Diseases · 2025

DOI: 10.1093/infdis/jiaf386 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift The Journal of Infectious Diseases, 2025. Verfasst von Jinzhi Zhang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Center of Infectious Diseases, West China Hospital of Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Amoxicillin, Anti-Bacterial Agents, Helicobacter Infections, HIV Infections. Die Arbeit nennt 38 Literaturangaben. Gefördert von: Advanced Discipline Deployment Fund of Sichuan University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Antiretroviral therapy (ART) has significantly increased the life expectancy of people living with human immunodeficiency virus (PLWH), resulting in a growing need for the treatment of Helicobacter pylori infections in this population. H. pylori treament among PLWH who are on ART can be challenging due to potential drug-drug interactions (H. pylori eradication drugs interact with ART drugs). This study aimed to evaluate the efficacy and safety of vonoprazan-amoxicillin (VA) dual therapy for H. pylori infection among PLWH.

Methods

A total of 201 treatment-naive, H. pylori­–positive PLWH on ART were enrolled to receive vonoprazan (20 mg twice daily) plus amoxicillin (1000 mg 3 times daily) for 14 days. H. pylori eradication status was assessed using the urease breath test ≥4 weeks after treatment. Patient compliance and adverse events (AEs) were recorded.

Results

Of the 201 participants, 181 (90.0%) completed the treatment course. Nineteen patients were lost to follow-up, and 1 discontinued treatment due to a rash. The eradication rates were 74.6% (150 of 201) by intention-to-treat analysis, 82.9% (150 of 181) by modified intention-to-treat analysis, and 90.6% (145 of 160) by per-protocol analysis. AEs occurred in 10 patients (5.0%), including abdominal distension in 5 and abdominal pain, nausea, diarrhea, fatigue, and rash, each occurring in 1 patient. Most AEs were mild and resolved spontaneously after treatment. Good compliance (odds ratio, 1.03 [95% confidence interval, 1.01–1.11]; P < .001) was independently associated with the efficacy of VA for H. pylori eradication.

Conclusions

VA dual therapy as a first-line treatment for H. pylori infection among PLWH on ART demonstrates good efficacy and safety. Clinical Trials Registration ChiCTR2400085762

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AmoxicillinAnti-Bacterial AgentsHelicobacter InfectionsHIV InfectionsPyrrolesSulfonamidesAdultFemaleHumansMaleMiddle AgedDrug Therapy, CombinationHelicobacter pyloriProton Pump InhibitorsTreatment Outcome

Stichwörter der Autor:innen

Helicobacter pyloriHIVamoxicillinvonoprazan

Substanzen

1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamineAmoxicillinAnti-Bacterial AgentsProton Pump InhibitorsPyrrolesSulfonamides

Autor:innen und Institutionen

  • Center of Infectious Diseases, West China Hospital of Sichuan University, Chengdu, China.
  • Laboratory of Infectious and Liver Diseases, Institute of Infectious Diseases, West China Hospital of Sichuan University, Chengdu, China.
  • Department of Infection, West China Tianfu Hospital of Sichuan University, Chengdu, China.
  • Department of Infectious Diseases, Zhaojue County People's Hospital, Xichang, China.
  • Helicobacter pylori Research Laboratory, School of Biomedical Sciences, Marshall Centre for Infectious Diseases Research and Training, University of Western Australia, Nedlands, Australia.

ORCID-Profile: Hong Li

Förderung

  • Advanced Discipline Deployment Fund of Sichuan University

Zitieren

APA

Zhang, J., Wang, Y., Chen, L., Feng, P., Song, X., Shen, Y., Ma, F., Tay, A. C. Y., Marshall, B. J., Tang, H., & Li, H. (2025). Efficacy and Safety of Vonoprazan-Amoxicillin Dual Therapy for Helicobacter pylori Infection Among People Living With HIV. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiaf386

Vancouver

Zhang J, Wang Y, Chen L, Feng P, Song X, Shen Y, et al. Efficacy and Safety of Vonoprazan-Amoxicillin Dual Therapy for Helicobacter pylori Infection Among People Living With HIV. The Journal of Infectious Diseases. 2025. doi:10.1093/infdis/jiaf386

BibTeX
@article{Zhang2025,
  author = {Zhang, Jinzhi and Wang, Ying and Chen, Liyu and Feng, Ping and Song, Xiaona and Shen, Yalin and Ma, Fanghua and Tay, Alfred C Y and Marshall, Barry J and Tang, Hong and Li, Hong},
  title = {Efficacy and Safety of Vonoprazan-Amoxicillin Dual Therapy for Helicobacter pylori Infection Among People Living With HIV},
  journal = {The Journal of Infectious Diseases},
  year = {2025},
  doi = {10.1093/infdis/jiaf386}
}
Kostenlos starten →